TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Steroids on Intra-dialytic Hypotension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients on hemodialysis who develop intra-dialytic hypotension.~Exclusion Criteria:~* Adrenal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Hydrocortisone (Type: ACTIVE_COMPARATOR): 100mg Hydrocortisone will be administered prior to hemodialysis
- Placebo (Type: PLACEBO_COMPARATOR): 100mg normal saline will be administered prior to hemodialysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Must have Crohn's disease or fistulizing Crohn's disease of at least 3 months duration~* Must have received Remicade, adalimumab or Cimzia at a dose approved for the treatment of Crohn's disease~* Must have failed or been intolerant to Remicade, Humira or Cimzia for treatment of Crohn's disease~* Must be 18 years of age or older~* Must have active Crohn's disease according to the Crohn's Disease Activity Index (CDAI \> =220 and \< =450).~Exclusion Criteria:~* Patients who have had any kind of bowel resection, diversions or placement of a stoma within 6 months~* Are pregnant, nursing or planning pregnancy (both men and women) while enrolled in the study or within 1 year after receiving study agent~* Patients who have received Remicade, Humira or Cimzia \< =8 weeks before the first administration of study drug~* Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug~* Patients with a history of or ongoing chronic or recurrent infectious disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (IP) (Type: PLACEBO_COMPARATOR): None
- Ustekinumab 1mg/kg (IP) (Type: EXPERIMENTAL): None
- Ustekinumab 3 mg/kg (IP) (Type: EXPERIMENTAL): None
- Ustekinumab 6 mg/kg (IP) (Type: EXPERIMENTAL): None
- Placebo IV - Responder - Placebo SC (MP) (Type: PLACEBO_COMPARATOR): None
- Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (Type: PLACEBO_COMPARATOR): None
- Ustekinumab IV - Responder - Placebo SC (MP) (Type: PLACEBO_COMPARATOR): None
- Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) (Type: EXPERIMENTAL): None
- Ustekinumab IV - Nonresponder - Placebo SC (MP) (Type: PLACEBO_COMPARATOR): None
- Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A ProspectiveTrial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients that will be undergoing a Left Laparoscopic Colon Resection~* Older than 18 years old~* ASA 1 to 3~* Elective surgeries~* Patients who willingly provide informed consent~Exclusion Criteria:~* Morbidly obese patients (BMI \>35)~* Patients with acute diverticulitis~* Patients with multiple previous abdominal surgeries~* Patients on anticoagulants~* Patients who can not, tolerate a major surgery~* Patients for whom electrosurgery is contraindicated~* Patients who are pregnant~* Patient with IBDs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- THUNDERBEAT (Type: OTHER): THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
- LIGASURE (Type: OTHER): LIGASURE energy device will be used for dissection of tissue and ligation of vessels

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zomig - Treatment of Acute Migraine Headache in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent by parent or legal guardian, and written assent provided by patient prior to any study specific procedures.~* Established diagnosis of migraine.~* History of a minimum of 2 migraine attacks (moderately or severely disabling)per month.~Exclusion Criteria:~* Any medical condition that may put the patient at increased risk with exposure to zolmitriptan or that may interfere with the safety or efficacy assessments.~* A history of basilar, ophthalmoplegic, or hemiplegic migraine headache or any potentially serious neurological condition that is associated with headache.~* Have had an unacceptable adverse experience following previous use of any 5HT1B/1D agonist drug.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: EXPERIMENTAL): ZOMIG 0.5 mg
- 3 (Type: EXPERIMENTAL): ZOMIG 2.5 mg
- 4 (Type: EXPERIMENTAL): ZOMIG 5.0 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of schizophrenia~* Must be an outpatient (not requiring hospitalization) now and for at least the past 8 weeks.~* Disease symptoms must meet a certain range as assessed by the clinician.~* Patient has experienced at least two episodes of clinical worsening of their condition. This could mean admission to a hospital or an emergency room visit. This could mean that a new medication was added, medication dose was increased, or medication was switched in order to better control symptoms of the condition.~* The patient must have an unsatisfactory response to their current medication or be experiencing negative effects of their current medication or not always take their current medication so that a change in current medication is desired.~Exclusion Criteria:~* Patients who are actively suicidal.~* Patients who are pregnant or nursing.~* Patients who have stopped past treatment with olanzapine because of adverse events, are treatment resistant or allergic to olanzapine, or have a condition which would prevent use of a long acting form of olanzapine.~* Patients with uncorrected narrow-angle glaucoma, seizures, uncontrolled diabetes, certain diseases of the liver, uncontrolled thyroid condition or other serious or unstable illness.~* Patients with Parkinson's disease, psychosis related to dementia or other related disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine Pamoate Depot (Type: EXPERIMENTAL): Olanzapine pamoate depot
- Olanzapine (Type: ACTIVE_COMPARATOR): Oral olanzapine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Noise Reduction Preferences in Teenagers and Pre-teens

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* mild, moderate, or moderate-severe bilateral sensorineural hearing loss~* native English speakers with ability to communicate verbally~* able to read and follow directions~* access to smartphone and willing to download a hearing aid app~* experienced hearing aid user (6+ months)~Exclusion Criteria:~* unable to follow verbal directions~* unable to communicate verbally~* unable to wear study devices for required home trials~* active middle ear infection~* unable to attend lab visits required for study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: EXPERIMENTAL): Participants will be fit with a commercially available hearing aid and tested using various strengths of the noise reduction feature.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinical signs and symptoms of VL and confirmatory parasitological microscopic diagnosis~* Patients aged \> 4 to \< 12 years who are able to comply with the study protocol.~* Patients for whom written informed consent has been signed by parents(s) or legal guardian~* Weight \< 30 kg~Exclusion Criteria:~* Patients who are relapse cases~* Patients who have received any anti-leishmanial drugs in the last 6 months~* Patients with severe malnutrition (for children aged \<5 years, weight-for-height WHO reference curves by gender, z score \<-3; for children 5-12 years, BMI-for-age WHO reference curves for gender, z score \< -3)~* Patients with positive HIV diagnosis~* Patients with previous history of hypersensitivity reaction to miltefosine~* Patients suffering from a concomitant severe infection such as Tuberculosis (TB) or any other serious underlying disease (cardiac, renal, hepatic) which would preclude evaluation of the patient's response to study medication~* Patients suffering from other conditions associated with splenomegaly such as schistosomiasis~* Pregnant or lactating women or female patient in childbearing age (reached menarche)~* Patients with haemoglobin \< 5g/dl~* Patients with White Blood Cells (WBC) \< 1 x 10³/mm³~* Patients with platelets \< 40,000/mm³~* Patients with abnormal liver function (ALT and AST) tests of more than three times the normal range.~* Patients with bilirubin more than 1.5 times the upper normal range~* Patients with serum creatinine above the upper limit of normal (ULN) for age and gender.~* Patients with clinical signs of severe VL disease such as jaundice and bleeding~* Patients who cannot comply with the planned scheduled visits and procedures of the study protocol

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Miltefosine (Type: EXPERIMENTAL): allometric dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided Selective Supraclavicular Nerve Block for Postoperative Pain Control in Pediatric Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients receiving Hickman catheter, chemoport, or Perm cath implantation (3 years ≤, \<18 years)~* One or more of the parents (or guardians), after hearing and understanding a sufficient explanation about this clinical trial, decides to participate voluntarily and agrees in writing to abide by the precautions~* In the case of a study subject aged seven years or older, a person who voluntarily decides to participate in this clinical trial and agrees in writing to abide by the precautions after hearing and understanding a sufficient explanation about this clinical trial~Exclusion Criteria:~* Patients who undergo surgery other than the surgery.~* Patients with diseases whose sensitivity to pain is different from that of the general public~* Unstable vital signs (heart rate, blood pressure)~* General contraindications of Ropivacaine~* Patients with a history of allergy to opioids~* Severe renal dysfunction (Creatinine\> 3.0 mg/dl)~* Severe liver dysfunction (aspartate transaminase \> 120 unit/L, alanine aminotransferase \> 120 unit/L)~* Peripheral nervous system abnormalities~* At risk of malignant hyperthermia~* Other cases that the researcher judges to be inappropriate

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Selective supraclavicular nerve block (Type: EXPERIMENTAL): After induction of anesthesia, the anesthesiologist sterilizes the skin of the area to be punctured. In the test group, an Ultrasound-guided selective supraclavicular nerve block is performed using 0.5% Ropivacaine 0.1mL/kg (Maximum dose: 5mL).
- Control (Type: ACTIVE_COMPARATOR): The nerve block is not performed in the control group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primary hypercholesterolemia treated with any statin at any dose, for at least 3 months with a ldl cholesterol above 115 mg/dl (esc 2003 recommendations).~Exclusion Criteria:~* pregnant or breast feeding women~* Lipid-lowering agents including hmg-coa reductase inhibitors other than the current statin, fish oils, cholestyramin, niacin (\>200 mg/day) and fibrates taken within the 3 months preceding visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ \[greater than or equal to\] 40 years of age~* If a participant in the previous DIC3-08-05 study, completed the study and did not discontinue for lack of efficacy or safety~* Has a diagnosis of OA of the hip or knee with ongoing knee and/or articular hip pain~* Is a current chronic user of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen for his/her OA pain and is anticipated to benefit from continuous treatment with therapeutic doses of NSAIDs. A current chronic user is defined as a subject who has used these treatments for ≥ \[greater than or equal to\] 20 days of the last 30 days before screening~Exclusion Criteria:~* Has a known history of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any nonsteroid anti-inflammatory drugs (NSAIDs), including diclofenac~* Requires chronic use of opioid or opioid combination products to control OA pain of the knee or hip~* Has any clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease~* Has significant difficulties swallowing capsules or is unable to tolerate oral medication

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diclofenac Capsules 35 mg bid or tid (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diagnosed as autism with irritability~Exclusion Criteria:~* patients who has ever been treated with aripiprazole

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with Type 1 diabetes (T1D) or Type 2 diabetes (T2D)~* Body mass Index (BMI) of 18.5 to 30.0 kilograms per meter squared (kg/m2) for T1D, or 18.5 to 35.0 kg/m2 for T2D~* Hemoglobin A1c (HbA1c) ≤10%~Exclusion Criteria:~* Have significant changes in insulin regimen and/ or unstable blood sugar control within the past 3 month~* Have received a total daily dose of insulin \>1.2 units per kilogram (U/kg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Glucagon Nasal Powder (Type: EXPERIMENTAL): A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally.
- Glucagon Hydrochloride Solution (Type: ACTIVE_COMPARATOR): A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetics of Disulfiram for Cocaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-IV diagnosis criteria for opioid dependence, as determined by documentation of prior treatment for addiction; signs of withdrawal; self-reported history of dependence for at least 1 year; and a positive urine test for opioids~* Meets DSM-IV diagnosis criteria for cocaine dependence, as determined by self-reported use of cocaine at least once weekly for at least 1 month prior to study entry; a positive urine test for cocaine; and a score greater than 3 on the Severity Dependence Scale~* If female, willing to use contraception throughout the study~Exclusion criteria:~* Meets DSM-IV diagnosis criteria for dependence on any drugs other than opiates, cocaine, or tobacco~* Current major psychiatric illness, including schizophrenia, bipolar disorder, or other psychotic disorder~* Current suicidal or homicidal ideation~* Current use of a prescribed psychotropic medication that cannot be discontinued~* History of or current major medical illness, including major heart, kidney, endocrine, or liver disorder; abnormal liver function (SGOT or SGPT levels three times greater than normal);~* High risk factor for heart disease, seizure disorders, or any illness for which disulfiram or methadone treatment would be inadvisable~* Currently taking metronidazole or clotrimazole~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Disulfiram, Methadone (w/lactose) & CBT (Type: EXPERIMENTAL): Participants are randomly assigned to receive a daily dose of 250 mg of disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving study medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
- Placebo, Methadone (w/lactose) & CBT (Type: ACTIVE_COMPARATOR): Participants are randomly assigned to receive a daily dose of a sugar pill to mimic the experimental drug disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving all medication at week 14, at which point they will undergo a 4-week methadone detoxification period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete